Our Initial Entry
5 Day VWAP
Our Current Returns
Dec 16 2020
Our Current Returns
Who are Neurotech International Ltd (ASX: NTI)?
NTI has an exclusive license on unique cannabis strains that have high CBD but low THC.
NTI is trying to prove its cannabis strains can be effective in the treatment of ADHD, epilepsy, and autism.
Cannabidiol - or CBD - is the part of the cannabis plant that is the most promising from a medical perspective and is not psychoactive. THC is the psychoactive component of a cannabis plant and anything over 0.3% is classified as a narcotic.
NTI’s strains contain unique cannabinoids, but less than 0.3% THC - which means it's easier to pass through regulatory pathways and bring products to market.
NTI has begun its first clinical trials on children aged between 5 and 17 years with Autism Spectrum Disorder (ASD).
It is early days for NTI, but if the company can clinically prove its genetic strains are effective in the treatment of neurological disorders, it would make NTI a very valuable company.
We invested for this upside.
We like NTI’s assets and now it has reached the Clinical Trial stage. We have seen outsized returns for successful cannabis stocks that can clinically prove effectiveness of cannabis strains.
GW Pharmaceuticals (NASDAQ: GWPH) and Tilray (NASDAQ: TLRY) are the best examples. GW Pharmaceuticals is capped at $6.9BN and Tilray is currently hovering around the $3BN market cap.
NTI is currently capped at $43M (with $3.5M cash at March 31st), and is an early stage, speculative investment - there is no guarantee of success, however the upside is large.
Investment Milestones for NTI
✅ Initial Investment @ 5c
✅ Top Slice
🔲 Free Carry
🔲 Take Profit
🔲 Price increases 300% from initial entry
🔲 Price increases 500% from initial entry
🔲 Price increases 1000% from initial entry
🔲 12 Month Capital Gain Discount
🔲 Hold remaining Position for next 2+ years
Exit Position: S3 Consortium Pty Ltd and Associated Entities no longer holds shares in NTI